* 搜尋
* 核能資訊中心
* 中心簡介
* 相關資訊
* 瀏覽人數
今天: 10308
昨天: 19414
本月: 424491
總計: 1216700
國際核能現況 : NRG receives funding for nuclear medicine R&D centre
發表人 nicenter 於 2019/1/21 9:40:58 (78 人讀取)

NRG receives funding for nuclear medicine R&D centre

The Advancing Nuclear Medicine consortium, led by the Nuclear Research and Consultancy Group (NRG), has been awarded a EUR6.8 million (USD7.7 million) subsidy to develop FIELD-LAB. This Dutch initiative is aimed at accelerating the development and introduction of new radiopharmaceuticals.

The Energy & Health Campus in Petten (Image: NRG)

The contribution by the Kansen voor West (which translates as Opportunities for the West) organisation is from the European Fund for Regional Development (EFRO). NRG - operator of the EU's High Flux Reactor at Petten in the Netherlands - said the contribution would "help to intensify and accelerate FIELD-LAB development and implementation".

NRG's seven partners in the Advancing Nuclear Medicine consortium include various Dutch academic medical centres and industrial partners: the Netherlands Cancer Institute - Antoni van Leeuwenhoek, Stichting Voorbereiding Pallas, Radboudumc, Erasmus MC, Amsterdam UMC, NucMed and FutureChemistry. The proposal is also supported internationally by 15 organisations, including the German Cancer Research Centre and BTG, a Canadian pharmaceutical company.

NRG said FIELD-LAB is "a unique breeding ground for the development of new nuclear medicine, which are expected to take an increasing role in the personalised treatment of life-threatening diseases like cancer".

It describes FIELD-LAB as "a combination of nuclear infrastructure, partly existing, partly new, in combination with NRG's nuclear knowledge and expertise and the medical knowledge, expertise and product ideas of FIELD-LAB partners - 'a one-stop-shop' - that aims to enable and shorten the development and introduction of new nuclear medicine solutions and radiopharmaceutical drugs. In FIELD-LAB, companies and knowledge institutes can work together and combine their academic knowledge to execute radiopharmaceutical innovation projects."

FIELD-LAB aims to be a joint research and development centre for collaborations and partnerships, facilitating services including: radio-chemistry laboratory R&D services; development of production processes; research grade material supply; development and implementation of good manufacturing practices (GMP) processes; and GMP approved small batch material supply.

FIELD-LAB will be based at the Energy & Health Campus in Petten, adjacent to the High Flux Reactor, which produces about one-third of all commonly used medical isotopes worldwide.

"Several years ago, NRG turned its attention to stimulating the development of nuclear medications," said NRG Business Director Philippe Brouwers. "Among other things, we started collaborating with various partners such as university hospitals to draw up the plans for FIELD-LAB. Some 30,000 patients per day now benefit from the products we're creating in Petten. With this subsidy, we can start realising FIELD-LAB and in that way help even more patients in the future."

Researched and written by World Nuclear News

source: http://www.world-nuclear-news.org/Articles/NRG-receives-funding-for-nuclear-medicine-R-D-cent

2019/2/20 10:18:29 - Public hearing for Whiteshell licence renewal
2019/2/20 10:16:05 - Russia's Kola plant completes second WANO review
2019/2/20 10:09:05 - 回應環團抗議興達電廠更新計畫 台電:減開發增綠地 救空氣護溼地立場一致
2019/2/20 10:07:34 - 核二未來面臨燃料池滿 新北稱「目前尚有空間」 台電:避重就輕、張飛打岳飛
2019/2/18 10:18:09 - NRC seeks input on legacy uranium cleanup
2019/2/18 10:14:08 - BP forecasts nuclear growth to 3400 TWh by 2040
2019/2/18 10:11:32 - Melted fuel photographed at Fukushima
2019/2/18 10:09:53 - Search for UK repository site resumes
2019/2/15 13:56:22 - NRC terminates US MOX plant authorisation
2019/2/15 13:54:09 - Foratom highlights role of nuclear in meeting EU's target






30013 新竹市光復路二段101號 北育成三樓309室 電話:(03)571-1808 傳真:(03)572-5461 Email: nicenter[@]nicenter.org.tw